Wnt inhibitors reduce the unfolded protein response and enhance bortezomib-induced cell death in multiple myeloma

被引:2
|
作者
Spaan, Ingrid [1 ]
van Nieuwenhuijzen, Niels [1 ,2 ]
Kimman, Thomas [1 ]
Rockx-Brouwer, Dedeke [1 ]
Tieland, Ralph G. [1 ]
Maurice, Madelon M. [3 ,4 ]
Minnema, Monique C. [2 ]
Raymakers, Reinier A. [2 ]
Peperzak, Victor [1 ,5 ]
机构
[1] Univ Utrecht, Univ Med Ctr Utrecht, Ctr Translat Immunol, Utrecht, Netherlands
[2] Univ Utrecht, Univ Med Ctr Utrecht, Dept Hematol, Utrecht, Netherlands
[3] Oncode Inst, Utrecht, Netherlands
[4] Univ Utrecht, Univ Med Ctr Utrecht, Ctr Mol Med, Dept Cell Biol, Utrecht, Netherlands
[5] Univ Utrecht, Univ Med Ctr Utrecht, Ctr Translat Immu nol, NL-3584 CX Utrecht, Netherlands
关键词
DISEASE;
D O I
10.1182/bloodadvances.2022008442
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The Wnt pathway is one of the main regulators of cell growth and is essential for embryonic development and tissue homeostasis.1 Dysregulation of the Wnt pathway is involved in the patho-genesis of many types of carcinomas and is associated with certain hematological cancers, including multiple myeloma (MM).2-4 Several studies, primarily using cell lines and mouse models, reported that MM plasma cells (PCs) carry a functional Wnt/??-catenin signaling pathway that promotes cell survival.3-7 Despite new and successful treatment options, MM remains incurable because of clinical, genetic, and transcriptomic heterogeneity, which ultimately results in therapy resistance and relapse. Thus, an unmet need exists to find new therapeutic targets and improve responses to approved drugs. In the canonical Wnt pathway, Wnt ligands bind and activate Frizzled receptors and LRP5/6 cor-eceptors to recruit components of the ??-catenin destruction complex.1,3 Subsequent stabilization of nonphosphorylated ??-catenin results in the transcription of Wnt target genes. Here, we targeted 2 pathway components to inhibit Wnt signaling in MM cells. Inhibition of tankyrase promotes degradation of ??-catenin owing to stabilization of Axin, which is the concentration-limiting component of the ??-catenin destruction complex.8 Inhibition of porcupine, an enzyme required for the secretion of all human Wnt ligands, was shown to reduce Wnt signaling in vitro and in a mouse model.9 We demonstrate that targeting Wnt signaling promotes cell death of patient-derived MM cells and down-regulates genes involved in the unfolded protein response (UPR). Subsequently, we show that Wnt inhibitors enhance bortezomib (BTZ)-induced cell death in primary MM cells. First, we tested the functionality of tankyrase inhibitor (TNKSi) XAV939 and porcupine inhibitor (PORCi) C59 in MM cell lines. Single-drug exposure in MM1.S blocked ??-catenin upregulation by Wnt3a-conditioned medium in case of TNKSi and downregulated ??-catenin expression in case of PORCi (Figure 1A). Treatment with TNKSi caused only moderate apoptosis in MM1.S and L363, ranging from 0.2% to 3.9% specific apoptosis at 10 to 40 ??M TNKSi and 3.9% to 29.1% specific apoptosis at 5 to 10 ??M PORCi (supplemental Figure 1A). The inhibitor combination induced more than additive cell death in MM1.S, with specific apoptosis increasing to 57.1% for 20 ??M TNKSi and 10 ??M PORCi (supplemental Figure 1A,B). A significant impact on the number of viable cells was observed after 7 days of treatment (supplemental Figure 1C). We also demonstrated a significant reduction in transcriptional Wnt reporter activity after treatment with both inhibitors (Figure 1B). In addition to MM1.S and L363, the combination of Wnt inhibitors was effective in MM cell lines INA-6 and KMS12-PE (supplemental Figure 1D). In summary, these data show that the Wnt pathway can be inhibited by a combination of TNKSi and PORCi and affects cell survival in MM cell lines.
引用
收藏
页码:1103 / 1107
页数:5
相关论文
共 50 条
  • [1] Bortezomib-induced rhabdomyolysis in multiple myeloma
    Cibeira, M. Teresa
    Mercadal, Santiago
    Arenillas, Leonor
    Muntanola, Anna
    Salamero, Olga
    Blade, Joan
    ACTA HAEMATOLOGICA, 2006, 116 (03) : 203 - 206
  • [2] Bortezomib-induced "BRCAness" sensitizes multiple myeloma cells to PARP inhibitors
    Neri, Paola
    Ren, Li
    Gratton, Kathy
    Stebner, Erin
    Johnson, Jordan
    Klimowicz, Alexander
    Duggan, Peter
    Tassone, Pierfrancesco
    Mansoor, Adnan
    Stewart, Douglas A.
    Lonial, Sagar
    Boise, Lawrence H.
    Bahlis, Nizar J.
    BLOOD, 2011, 118 (24) : 6368 - 6379
  • [3] Mechanisms, biologic sequelae and clinical benefits of bortezomib-induced immunogenic cell death in multiple myeloma
    Gulla, Annamaria
    Morelli, Eugenio
    Samur, Mehmet
    Hideshima, Teru
    Bianchi, Giada
    Fulciniti, Mariateresa
    Rao, Prabhal
    Talluri, Srikanth
    Tai, Yu-Tzu
    Chauhan, Dharminder
    Carrasco, Ruben
    Munshi, Nikhil
    Anderson, Kenneth C.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E162 - E162
  • [4] Clinically relevant GABARAP deficiency abrogates bortezomib-induced immunogenic cell death in multiple myeloma
    Zhao, Liwei
    Shen, Zhe
    Kroemer, Guido
    Kepp, Oliver
    ONCOIMMUNOLOGY, 2024, 13 (01):
  • [5] BORTEZOMIB-INDUCED UNFOLDED PROTEIN RESPONSE INCREASES ONCOLYTIC HSV-1 REPLICATION RESULTING IN SYNERGISTIC, NECROPTOTIC CELL DEATH
    Hurwitz, Brian
    Yoo, Ji Young
    Bolyard, Chelsea
    Yu, Jun-Ge
    Wojton, Jeffery
    Zhang, Jianying
    Bailey, Zachary
    Eaves, David
    Cripe, Timothy
    Old, Matthew
    Kaur, Balveen
    NEURO-ONCOLOGY, 2013, 15 : 47 - 47
  • [6] Bortezomib-Induced Muscle Toxicity in Multiple Myeloma
    Guglielmi, Valeria
    Nowis, Dominika
    Tinelli, Martina
    Malatesta, Manuela
    Paoli, Laura
    Marini, Matteo
    Manganotti, Paolo
    Sadowski, Radoslaw
    Wilczynski, Grzegorz M.
    Meneghini, Vittorio
    Tomelleri, Giuliano
    Vattemi, Gaetano
    JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2017, 76 (07): : 620 - 630
  • [7] Bortezomib-induced Pneumonitis During Bortezomib Retreatment in Multiple Myeloma
    Yamaguchi, Takeshi
    Sasaki, Masaoki
    Itoh, Kuniaki
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2012, 42 (07) : 637 - 639
  • [8] Glycogen Synthase Kinase-3 regulates multiple myeloma cell growth and bortezomib-induced cell death
    Francesco Piazza
    Sabrina Manni
    Laura Quotti Tubi
    Barbara Montini
    Laura Pavan
    Anna Colpo
    Marianna Gnoato
    Anna Cabrelle
    Fausto Adami
    Renato Zambello
    Livio Trentin
    Carmela Gurrieri
    Gianpietro Semenzato
    BMC Cancer, 10
  • [9] Bortezomib-Induced Proinflammatory Macrophages Contribute to Multiple Myeloma Cell Aggressiveness
    Katz, Ofrat Beyar
    Ben-Tsedek, Neta
    Avivi, Irit
    Alishekevitz, Dror
    Timaner, Michael
    Miller, Valeria
    Lindzen, Moshit
    Yarden, Yosef
    Shaked, Yuval
    BLOOD, 2015, 126 (23)
  • [10] Glycogen Synthase Kinase-3 regulates multiple myeloma cell growth and bortezomib-induced cell death
    Piazza, Francesco
    Manni, Sabrina
    Tubi, Laura Quotti
    Montini, Barbara
    Pavan, Laura
    Colpo, Anna
    Gnoato, Marianna
    Cabrelle, Anna
    Adami, Fausto
    Zambello, Renato
    Trentin, Livio
    Gurrieri, Carmela
    Semenzato, Gianpietro
    BMC CANCER, 2010, 10